Q4 2024 Curis Inc Earnings Call Transcript

Mar 31, 2025 / 12:30PM GMT

Release Date Price: €1.96 (-10.09%)

Transcript 10-K8-K8-K

Key Points

Positve

Curis Inc (CRIS) received encouraging feedback from the EMA and FDA on the potential for conditional marketing authorization in Europe and accelerated approval in the US for their TakeAim lymphoma study.
The TakeAim lymphoma study is now considered registrational for both the US and Europe, accelerating the development timeline for emavusertib.
Emavusertib has been granted orphan drug designation for primary CNS lymphoma in both the US and Europe.
The clinical data for emavusertib in combination with ibrutinib showed promising results, with significant tumor burden reduction and objective responses in both BTKi-experienced and BTKi-naive PCNSL patients.
Curis Inc (CRIS) reported a decrease in net loss and reduced R&D and G&A expenses compared to the previous year, indicating improved financial management.

Negative

Curis Inc (CRIS) reported a net loss of $9.6 million for the fourth quarter of 2024, highlighting ongoing financial challenges.
The company continues to face risks and uncertainties related to forward-looking statements and actual results may differ materially.
The cash runway has been extended only until the fourth quarter of 2025, indicating potential future funding needs.
There is uncertainty regarding the number of patients needed to meet FDA requirements for individual component contributions in the emavusertib study.
The company is still in the early stages of discussions with potential partners, indicating that strategic partnerships are not yet secured.

Operator

Good morning and welcome to Curis' fourth quarter 2024 business update call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Diantha Duvall, Curis' Chief Financial Officer. Diantha, please go ahead.

Diantha Duvall Curis Inc;Chief Financial Officer

Thank you and welcome Curis' fourth quarter 2024 business update call. Before we begin, I would like to encourage everyone to go to the investor section of our website at www.curis.com to find our fourth quarter 2024 business update press release and related financial tables.

I would also like to remind everyone that during the call, we will be making forward-looking statements which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings.

Joining me on today's call are Jim Dentzer, President and Chief Executive

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.